Replies to post #224632 on Biotech Values

[dangerM]

SBPH I haven't fully made up my mind and I haven't listened to the conference call yet, but I found their presentation slides somewhat fuzzy in how conclusions are reached.

https://ir.springbankpharm.com/static-files/32e1dbed-d046-400a-b67d-636720f11d6a

As well, there's this thread on Twitter I have to ponder about (read above and below this post: "So it could be a dinucleotide prodrug of a bulky nuc. Their MOA theories are not very good at all, fwiw"

oh wow, interesting. So it could be a dinucleotide prodrug of a bulky nuc. Their MOA theories are not very good at all, fwiw $SBPH

— Jssr (@juliaskripkaser) April 10, 2019

)

So, well, I do not hold the same amount of shares as of my previous post. But that was planned due to a competitor's, more specifically ASMB's presentation of clinical data tomorrow.